Actively Recruiting

Phase 2
Age: 2Years +
All Genders
NCT06855745

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

Led by Alphyn Biologics · Updated on 2025-08-01

72

Participants Needed

12

Research Sites

35 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).

CONDITIONS

Official Title

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

Who Can Participate

Age: 2Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female participants aged 2 years or older at consent
  • Clinical diagnosis of atopic dermatitis with a history of at least 6 months (3 months for children under 6 years)
  • Mild to moderate atopic dermatitis with vIGA score of 2 or 3 at screening and Day 1
  • Atopic dermatitis affecting head, neck, trunk (excluding groin/genitals), or limbs covering 2% to 20% body surface area
  • At least one lesion of approximately 5 cm2 or larger, not on hands, feet, or genitalia
  • Eczema Area and Severity Index (EASI) score between 3 and 21 at screening and Day 1
  • Peak itch (pruritus) score of at least 4 at screening and Day 1
  • Stable use of allowed oral and topical medications for at least 14 days before Day 1
  • Willing to avoid other topical products on affected areas during treatment
  • Able and willing to comply with all study procedures and visits
  • Females must not be pregnant or breastfeeding and either not of childbearing potential or agree to follow contraceptive guidelines
  • Males must agree to follow contraceptive guidelines
Not Eligible

You will not qualify if you...

  • Unstable or rapidly changing atopic dermatitis in the 4 weeks before Day 1
  • Other skin disorders, pigmentation issues, or scarring affecting assessment
  • Atopic dermatitis only on hands or feet without other typical areas involved
  • Other types of atopic dermatitis
  • Recent or planned treatments that may affect atopic dermatitis course
  • UV light therapy or artificial UV exposure within 2 weeks before screening or planned during study
  • Use of biologic agents within 12 weeks or 5 half-lives before Day 1
  • Use of systemic corticosteroids or immunosuppressants within 4 weeks before Day 1
  • Use of systemic antibiotics within 2 weeks before Day 1
  • Use of topical treatments for atopic dermatitis (except bland emollients) within 1 week before Day 1
  • Treatment for cancer (except certain skin cancers) within last 5 years
  • Other active skin conditions that may interfere with evaluation
  • Severe or uncontrolled major organ diseases or infections in past 3 months
  • Recent use of significant systemic therapies judged clinically important
  • Major surgery or trauma within 3 months before screening or planned during study
  • Hypersensitivity to zabalafin or hydrogel components
  • Uncontrolled or severe depression, suicidal thoughts, or behavior
  • Positive pregnancy test within 24 hours before randomization
  • Live vaccines within 30 days before treatment; certain COVID-19 vaccines allowed
  • Participation in another investigational drug trial within 90 days
  • Investigator site staff or family members involved in the study
  • History of substance or alcohol abuse in past 6 months
  • Any medical or psychiatric condition that poses risk or interferes with study participation or results interpretation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Canopy Clinical Northern Beaches

Brookvale, New South Wales, Australia, 2100

Actively Recruiting

2

Momentum Clinical Research

Darlinghurst, New South Wales, Australia, 2010

Actively Recruiting

3

Premier Specialists

Kogarah, New South Wales, Australia, 2217

Actively Recruiting

4

St George Dermatology

Kogarah, New South Wales, Australia, 2217

Actively Recruiting

5

Novatrials

Kotara, New South Wales, Australia, 2289

Actively Recruiting

6

Innovate Clinical Research

Waitara, New South Wales, Australia, 2077

Actively Recruiting

7

Canopy Clinical Wollongong

Wollongong, New South Wales, Australia, 2500

Actively Recruiting

8

The Skin Center

Benowa, Queensland, Australia, 4217

Actively Recruiting

9

Momentum Clinical Research

Wellers Hill, Queensland, Australia, 4012

Actively Recruiting

10

Veracity Clinical Research

Woolloongabba, Queensland, Australia, 4102

Actively Recruiting

11

Canopy Clinical Altona North

North Altona, Victoria, Australia, 3025

Actively Recruiting

12

Captain Stirling Medical Centre

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

Loading map...

Research Team

D

Dr. Lynda Spelman

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. | DecenTrialz